North America Pharmaceutical Analytical Testing Outsourcing Market to reach $10,191 million by 2035

North America pharmaceutical analytical testing outsourcing market was valued at $4,853.5 million in 2025 and is projected to reach $10,191 million by 2035, growing at a CAGR of 7.7% during the forecast period 2026 to 2035, according to a new report by the Orion Market Research. The North American Pharmaceutical Analytical Testing Outsourcing Market is growing due to multiple factors, including increasing R&D activities, rising complexity of drug molecules, advanced technology adoption, and the need for cost and time efficiency. Among these, stringent regulatory mandates stand out as a major growth driver. Stringent FDA mandates, including ICH Q2 (R2) and Q14 adoption and stricter nitrosamine and impurity controls, are driving pharmaceutical companies to outsource testing for expertise, compliance, and faster results.

Browse the full report description of “North America Pharmaceutical Analytical Testing Outsourcing Market Size, Share & Trends Analysis Report by Product Type (API, Raw Materials, and Finished products), By Services (Bioanalytical services, Stability testing, Drug substance, Method development & Validation, and Others), Forecast Period (2026-2035)” of https://www.omrglobal.com/industry-reports/north-american-pharmaceutical-analytical-testing-outsourcing-market

FDA Mandates Fuels Analytical Testing Outsourcing Market Demand

The U.S. FDA’s increasing focus on safety, data integrity, and quality has raised the bar for pharmaceutical testing. Adoption of ICH Q2 (R2) for method validation and ICH Q14 for analytical procedure development has made analytical testing more complex, with a growing need for advanced instrumentation, skilled personnel, and robust documentation. Many in-house labs, particularly in smaller firms, lack the resources to fully meet these stringent requirements.

The FDA’s Revision 2 of "Control of Nitrosamine Impurities in Human Drugs" introduces the technically demanding Carcinogenic Potency Categorization Approach (CPCA). This has created a bottleneck demand for high-resolution mass spectrometry (LC-HRMS), as most in-house labs cannot detect impurities at the required parts-per-billion (ppb) levels. Consequently, the outsourcing market for nitrosamine surveillance is currently at a peak.

As a result, pharmaceutical companies are increasingly turning to outsourced analytical testing providers. These specialized partners offer expertise, state-of-the-art technology, and “audit-ready” processes to ensure regulatory compliance. They also help reduce risk during FDA inspections and accelerate drug development timelines. Outsourcing also allows companies to focus on core R&D while mitigating the challenges of meeting heightened regulatory standards.

Key Developments in the North America Pharmaceutical Analytical Testing Outsourcing Market 

• In March 2024, LGM Pharma announced a significant expansion of its standalone analytical testing services (ATS), increasing capacity by 50% and investing over $2?million to enhance its capabilities in method development, validation, stability testing, and advanced analytical assays. The expansion also includes new suppository manufacturing capabilities, providing broader CDMO support alongside analytical services.

• In September 2024, Pace Life Sciences acquired Catalent’s small molecule analytical services facility in North Carolina. This expands Pace’s analytical testing capabilities for both small and large molecules. It also strengthens its U.S. service network and enhances offerings from early research to commercialization. The expanded capacity aims to deliver faster, more flexible, and reliable outsourced analytical testing for pharma and biopharma clients.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
• Product Type
• Services

• Competitive Landscape – Charles River Laboratories International, Inc., Eurofins Scientific SE, Intertek Group plc, Pace Analytical Services, LLC and SGS S.A.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

North American Pharmaceutical Analytical Testing Outsourcing Market Report Segment

By Product Type

• API
• Raw Materials
• Finished products

By Services

• Bioanalytical services
• Stability testing
• Drug substance
• Method development & Validation
• Others (Quality Testing)

North American Pharmaceutical Analytical Testing Outsourcing Market Report Segment by Region

• United States
• Canada

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/north-american-pharmaceutical-analytical-testing-outsourcing-market